Soluble cytokine receptor CD30 in atopic disorders: a case-control study

Area of Science:

• Immunology
• Allergy Research
• Biomarker Discovery

Background:

• CD30, a cytokine receptor and T cell activation marker, is linked to TH2 cytokine IL-4 production.
• This association suggests CD30's potential role in atopic disorders and as a therapeutic target.

Purpose of the Study:

• To investigate the association between elevated soluble CD30 (sCD30) levels and atopic disorders.
• To determine if sCD30 remains a significant predictor after accounting for other atopy risk factors.

Main Methods:

• A nested case-control study evaluated sCD30 levels in blood donors.
• Cases (n=60) had allergic symptoms and elevated IgE; controls (n=59) did not.
• Enzyme-linked immunosorbent assay (ELISA) measured sCD30; logistic regression analyzed odds ratios (OR).

Main Results:

• Mean sCD30 levels were higher in cases (75 U/mL) than controls (35 U/mL).
• Elevated sCD30 was found in 65% of cases vs. 32% of controls (OR 3.9).
• sCD30 remained a significant predictor (OR 3.7) after adjusting for smoking, age, and gender.

Conclusions:

• Results support CD30's involvement in atopic disorder pathogenesis.
• This role is independent of eosinophilia and family history of allergy.